Atlas Trials

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

Clinical trial NCT06228053 · RECRUITING

Trial details

NCT number
NCT06228053
Sponsor
Syntrix Biosystems, Inc.
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Castration-resistant Prostate Cancer
Start date
2024-11-18
Primary completion
2027-06-30
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.